Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform

Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform

Abstract Background Socioeconomic differences in receipt of adjuvant treatment contribute to persistent disparities in breast cancer (BCA) outcomes, including survival. Adjuvant endocrine therapy (AET) substantially reduces recurrence risk and is recommended by clinical guidelines for nearly all wom...

Full description

Bibliographic Details
Main Authors:	Kirsten Y. Eom, G. J. van Londen, Jie Li, Bassam Dahman, Cathy Bradley, Lindsay M. Sabik
Format:	Article
Language:	English
Published:	BMC 2021-05-01
Series:	BMC Cancer
Subjects:	Breast cancer Adjuvant endocrine therapy Massachusetts health reform Health insurance Cancer registry
Online Access:	https://doi.org/10.1186/s12885-021-08149-0

Similar Items

Does patient health literacy impact adherence to adjuvant endocrine therapy in breast cancer patients?
by: Keim-Malpass J, et al.
Published: (2018-12-01)

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
by: Julia Foldi, et al.
Published: (2023-06-01)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
by: Leah K. Lambert, et al.
Published: (2018-07-01)

Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer
by: Brett J, et al.
Published: (2018-12-01)

Longitudinal Trends in Illness Perception and Depression during Adjuvant Breast Cancer Endocrine Therapy: A Prospective Observational Study
by: Seul Ki Park, et al.
Published: (2021-09-01)

Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer
by: Leah K. Lambert, et al.
Published: (2021-04-01)

Use of Adjuvant Endocrine Therapy Among Post-Menopausal Breast Cancer Patients in Malaysia
by: Saiful Bahri A, et al.
Published: (2021-02-01)

Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review
by: Kirsti I. Toivonen, et al.
Published: (2020-12-01)

Health belief about adjuvant endocrine therapy in premenopausal breast cancer survivors: a qualitative study
by: Xu L, et al.
Published: (2019-09-01)

Are another 5 years of adjuvant aromatase inhibitor therapy needed?
by: Mo QG, et al.
Published: (2016-11-01)

Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer
by: Kirsti I. Toivonen, et al.
Published: (2021-07-01)

Prevalence and determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore
by: Eskinder Eshetu Ali, et al.
Published: (2017-01-01)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
by: Roberta Rosso, et al.
Published: (2023-01-01)

The Importance of Health Insurance Reform
by: Nancy Landon Kassebaum
Published: (1995-10-01)

Fear of cancer recurrence in South Korean survivors of breast cancer who have received adjuvant endocrine therapy: a cross-sectional study
by: Seul Ki Park, et al.
Published: (2023-07-01)

Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence
by: Brett J, et al.
Published: (2018-02-01)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
by: Hao Liao, et al.
Published: (2022-05-01)

Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trialResearch in context
by: Vivianne C.G. Tjan-Heijnen, et al.
Published: (2023-04-01)

Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey
by: Marie-France Savard, et al.
Published: (2021-12-01)

The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy
by: Haoran Jiang, et al.
Published: (2022-04-01)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
by: Giacomo Pelizzari, et al.
Published: (2018-09-01)

Adjuvant systemic therapy in older women with breast cancer
by: Leone J, et al.
Published: (2016-07-01)

Estimating the overall survival benefit of adjuvant chemo‐endocrine therapy in women over age 50 with pT1‐2N0 early stage breast cancer and 21‐gene recurrence score ≥26: A National Cancer Database analysis
by: Nickolas Stabellini, et al.
Published: (2023-10-01)

Real-life experiences and barriers to adjuvant chemotherapy in Saudi patients with advanced stage II and stage III colon cancer
by: Mesnad S Alyabsi, et al.
Published: (2024-01-01)

The net effects of medical malpractice tort reform on health insurance losses: the Texas experience
by: Patricia H. Born, et al.
Published: (2017-11-01)

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials
by: Laura Pala, et al.
Published: (2023-06-01)

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
by: Inga Bekes, et al.
Published: (2023-08-01)

Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients
by: Kirsten M. Woolpert, et al.
Published: (2024-04-01)

The Comparison of Direct Health Expenditures of Selected Insurance Organizations of Isfahan Province and Isfahan University of Medical Sciences, Iran, before and after Health Care Reform in Years 2013 and 2015
by: Reza Khadivi, et al.
Published: (2019-02-01)

Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women
by: Juliette Artignan, et al.
Published: (2023-11-01)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
by: Hong-Fei Gao, et al.
Published: (2021-10-01)

A Survey of Potentially Modifiable Patient-Level Factors Associated with Self-Report and Objectively Measured Adherence to Adjuvant Endocrine Therapies After Breast Cancer
by: Toivonen KI, et al.
Published: (2021-09-01)

Implementing Health Financing Reforms in Africa: Perspectives of Health System Stewards
by: Tom Achoki, et al.
Published: (2017-03-01)

Health reform in China: Developments and future prospects
by: Jiwei Qian
Published: (2022-12-01)

The Impact of Health System Reform Plan on the Cost of Inpatient Prescriptions of Health Insurance in Public Hospitals in Sari, Iran
by: Majid Saeedi, et al.
Published: (2020-10-01)

Reform and Transitional Adjustment of the Health Care System in Slovenia
by: Petra Došenović, et al.
Published: (2005-08-01)

Complexities in Adjuvant Endocrine Therapy for Breast Cancer in Female-to-Male Transgender Patients
by: Shoko Sato, et al.
Published: (2024-02-01)

HEALTH INSURANCE IN HEALTH REFORM IN UKRAINE
by: H. Tlusta
Published: (2014-03-01)

Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy?
by: Susan G. R. McDuff, et al.
Published: (2022-12-01)

Health surveillance and endocrine disruptors
by: William Waissmann